Diabetic neuropathy is a major complication of diabetes that results in the progressive deterioration of the sensory nervous system. Mitochondrial dysfunction has been proposed to play an important role in the pathogenesis of the neurodegeneration observed in diabetic neuropathy. Our recent work has shown that mitochondrial dysfunction occurs in dorsal root ganglia (DRG) sensory neurons in streptozotocin (STZ) induced diabetic rodents. In neurons, the nutrient excess associated with prolonged diabetes may trigger a switching off of AMP kinase (AMPK) and/or silent information regulator T1 (SIRT1) signaling leading to impaired peroxisome proliferatoractivated receptor γ coactivator-1α (PGC-1α expression/activity and diminished mitochondrial activity. This review briefly summarizes the alterations of mitochondrial function and proteome in sensory neurons of STZ-diabetic rodents. We also discuss the possible involvement of AMPK/ SIRT/PGC-1α pathway in other diabetic models and different tissues affected by diabetes.
Introduction
Diabetes may lead to a number of complications that affect various tissues: heart and skeletal muscle, retina, secretory glands, kidneys, and peripheral nerves. Chronic metabolic stress induced by hyperglycemia resulting from either low insulin production in type 1 diabetes or decreased peripheral sensitivity to insulin in type 2 diabetes affects cellular homeostasis in virtually all cell types. At the same time the cellular pathophysiology of diabetes-induced impairments remain controversial. Diabetic neuropathy most often develops in the midst of other complications observed in diabetes. The putative pathogenesis of diabetic neuropathy includes increased polyol pathway activity leading to the accumulation of sorbitol and fructose (Oates, 2002 (Oates, , 2008 , advanced glycation-end products produced by non-enzymatic glycation of proteins (Duran-Jimenez et al., 2009; Thornalley, 2002) , inappropriate activation of protein kinase C (Eichberg, 2002) and reduced neurotrophic support -maintenance of normal phenotype of neurons is impaired due to diabetes-induced loss of neurotrophic support by insulin, insulin-like growth factors (IGF-I, IGF-II), nerve growth factor (NGF) and neurotrophin-3 (NT-3) (Calcutt et al., 2008) . Mitochondrial dysfunction occurs in a range of diabetic complications and given their central role in controlling the bioenergetic status of the cell, may be considered a prime trigger of nerve degeneration (Sivitz and Yorek, 2010) . Our recent work has shown that mitochondrial dysfunction occurs in dorsal root ganglia (DRG) sensory neurons in STZ (streptozotocin)-diabetic mice and rats and is characterized by impaired electron transport complex activities, reduced rates of oxidative phosphorylation and aberrant physiology in axons (Akude et al., 2011; Chowdhury et al., 2010) . Studies in muscle, liver and cardiac tissues have shown that the AMP kinase (AMPK), silent information regulator T1 (SIRT1) and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) signaling axis senses the metabolic demands of cells and regulates mitochondrial function accordinglye.g. under nutrient starvation the pathway is activated to enhance ATP production (Feige and Auwerx, 2007; Puigserver et al., 1998) . SIRT1 and 3 are deacetylases that alter the functions of an array of proteins including enzymes and histones and thus have far-reaching effects on global gene expression. PGC-1α is a primary target of AMPK and SIRT1 that controls the expression of a family of proteins required for mitochondrial function, biogenesis and regeneration. Our general hypothesis is that in neurons, prolonged diabetes results in nutrient excess and polyol pathway-mediated diminishment of the NAD + /NADH ratio. This results in a switching off of AMPK and/or SIRT isoforms leading to impaired PGC-1α expression/activity and a subsequent decrease in mitochondrial respiratory enzyme chain activities.
Clinical impact and socio-economic burden of diabetes and diabetic neuropathy
Diabetes causes about 5% of all deaths globally each year. It has received an increased attention in recent decades due to its high prevalence and enormous economic burden on our society. According to the Canadian Diabetic Association, an estimated 285 million people world-wide have diabetes. With a further 7 million people developing diabetes each year, this number is expected to hit 438 million by 2030 (http://www.diabetes.ca/diabetes-and-you/what/prevalence/). Data from 1997, published in National Diabetes Fact Sheet, revealed that in the USA, 23.6 million children and adults had diabetes and that another 57 million were in a pre-diabetic condition. Of those, about 90-95% have non-insulin-dependent diabetes mellitus (Type 2 diabetes) and 5-10% have insulin-dependent diabetes mellitus (Type 1 diabetes). In the USA, approximately $116 billion was spent in 2007 to cover direct health service costs for treatment of diabetic complications that include retinopathy, nephropathy, heart disease, and neuropathy. The indirect costs were $58 billion due to disability, work loss, and premature mortality. About 60% to 70% people with diabetes have mild to severe forms of nervous system damage. The incidence of sensory and autonomic neuropathies in diabetic patients leads to incapacitating pain, digestive abnormalities, erectile dysfunction, heart arrhythmia, sensory loss, foot ulceration (up to 2 million Americans have this complaint), infection, gangrene and poor wound healing. In the USA in 1998, approximately $15 billion of heath service expenditure was associated with the neurological complications (sensory and autonomic neuropathy and blindness). The end result is often lower extremity amputation which accounts for approximately 80,000 cases each year in the USA. There is no effective therapy, only palliative treatment is available at the present time. These alarming figures are estimated to rise by approximately 5-fold over the next 10 years due to the epidemic in obesity and the associated increase in incidence and earlier time of onset of Type 2 diabetes ( from American Diabetes Association web site:
http://www.diabetes.org/diabetes-basics/diabetes-statistics/).
Neurodegenerative features of diabetic sensory neuropathy
Diabetic neuropathy, the most common form of peripheral neuropathies, occurs with similar functional, morphological, and metabolic changes documented in both human and animal models of Type 1 and 2 diabetes. The features of this disease are associated with a reduction of motor and sensory nerve conduction velocity and a wide range of structural changes in peripheral nerves that includes endoneurial microangiopathy, abnormal Schwann cell pathology, axonal degeneration, paranodal demyelination and loss of myelinated and unmyelinated fibers -the latter due to a dying-back of distal axons that presents clinically as reduced epidermal nerve fibre density (Estrella et al., 2008; Malik et al., 2005; Mizisin et al., 2007; Mizisin et al., 2002; Sima, 2004; Yagihashi, 1997) . The neurodegeneration is most profound in the longest axons of neurons, and defective axon regeneration impedes tissue reinnervation (Polydefkis et al., 2004) . Apoptosis-dependent loss of sensory or sympathetic neuron perikarya has not been found in diabetic humans or animals (Kamiya et al., 2006; Kamiya et al., 2005; Schmidt et al., 1997a; Schmidt et al., 1997b; Sidenius and Jakobsen, 1980) , although loss of small unmyelinated neurons does occur in long-term mouse models of diabetes (Kennedy and Zochodne, 2005) . The distal dying-back and formation of axonal dystrophy (with swellings) of axons are critical pathological features (Kennedy et al., 1996; Polydefkis et al., 2004; Schmidt et al., 1997b) and mimic axonal pruning and degeneration observed in the CNS and PNS in other pathological states (Nja and Purves, 1978) .
Mitochondria and diabetic neuropathy
Mitochondrial dysfunction has been implicated in the pathophysiology of diabetic complications. The muscle, heart, kidney, and nerves all demonstrate abnormalities of mitochondrial structure and function in both clinical and animal models of diabetes. Mutation or loss of proteins associated with mitochondrial function can lead to neuropathy that mimics that seen in diabetes, for example, loss of function of mitofusin-2 or bcl-w results in a length-dependent sensory fiber degeneration (Baloh et al., 2007; Courchesne et al., 2011; Pazyra-Murphy et al., 2009) . Studies on mitochondrial physiology in diabetic neuropathy lag behind those in other diabetic complications, such as in muscle, cardiomyopathy and nephropathy. Table 1 summarizes findings in an array of animal models, and in humans, in Type 1 and 2 diabetes with respect to analysis of functioning of the mitochondrial respiratory chain. In general, mitochondrial-based electron transport functions are diminished.
1. Altered mitochondrial oxidative phosphorylation and proteome in diabetic sensory neuropathy
Our recent published results on mitochondrial function in DRG of STZ-diabetic rats are in general agreement with those findings described in muscle, heart and kidney (Akude et al., 2011; Chowdhury et al., 2010; Zherebitskaya et al., 2009) . Rates of coupled respiration with pyruvate + malate (P + M; full respiratory chain) and with ascorbate + TMPD (Asc + TMPD; Complex IV) in lumbar DRG were unchanged up to 12 weeks of diabetes (Chowdhury et al., 2010) . By 22 weeks of diabetes, respiration with P + M was significantly decreased by 31-44% and with Asc + TMPD by 29-39% in STZ-diabetic rats compared to control. Attenuated mitochondrial respiratory activity of STZ-diabetic rats was significantly improved by insulin treatment ( Fig. 1 taken from (Chowdhury et al., 2010) ). Enzymatic activities of mitochondrial complexes I and IV and the Krebs cycle enzyme, citrate synthase, were decreased in mitochondria from DRG of 22 week STZ-diabetic rats compared to control ( Fig. 2 taken from (Chowdhury et al., 2010) ). The diabetes-induced factors causing reduced rates of respiratory complex activities remain poorly understood, however, investigators have begun to use proteomic and gene array techniques to identify alterations in gene expression that presumably underpin such changes in mitochondrial physiology (for example, see (Bugger et al., 2009) ). The stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics analysis of mitochondrial protein expression in the mitochondria from 22 week STZ-diabetic rats by our group revealed that diabetes altered the levels of an array of proteins (mitochondrial complexes -Complex I-V, tricarboxylic acid (TCA) cycle, oxidative stress, fatty acid utilization) associated with the mitochondrial function (Table 2 taken from (Akude et al., 2011) ). Reduced expression of oxidative phosphorylation genes have been found in Type 2 diabetes (Patti et al., 2003) , and decreased expression of the transcriptional regulator, nuclear respiratory factor 1 (NRF-1) and the translational co-activator, PGC-1α were observed in pre-diabetic and diabetic muscle (Mootha et al., 2003) . Our results showing reduced expression of NADH dehydrogenase Fe-S protein 3 (NDUFS3) and subunit IV of cytochrome c oxidase (COX IV) in lumbar DRG of STZ-induced diabetic mice ( Fig. 3 ) and rats (Chowdhury et al., 2010) are consistent with these findings and support the premise that reduced activity of the mitochondrial respiratory chain could result from a proteome alteration leading to reduced expression/activity of a range of mitochondrial components. We have proposed that this broad spectrum of protein expression changes underpin the altered activity and physiology of the mitochondria in neurons in diabetes resulting in impaired bioenergetics in axons and subsequent degeneration.
Oxidative stress in diabetic neuropathy
Oxidative stress has been implicated in the pathological process inducing nerve damage in diabetes (Obrosova, 2002; Vincent et al., 2004) . Oxidative stress, possibly triggered by vascular abnormalities and associated microangiopathy in the nerve (Cameron et al., 2001; Malik et al., 2005) , is a key pathological process inducing nerve damage in diabetes in humans and experimental models (Obrosova, 2002; Vincent et al., 2004) . Diabetes-induced oxidative stress in sensory neurons and peripheral nerve is demonstrated by increased production of reactive oxygen species (ROS) (Coppey et al., 2003; Nishikawa et al., 2000b; Oltman et al., 2009; Russell et al., 2002) , lipid peroxidation , protein nitrosylation (Obrosova et al., 2005a; Obrosova et al., 2005b) , and reduced levels of reduced glutathione (Ho et al., 2006; Obrosova et al., 2002) and ascorbate . The neurodegenerative outcome is energy failure in the nerve, observed as a decrease in high energy intermediates (e.g. phosphocreatine) (Obrosova, 2002; Vincent et al., 2004) , impaired axonal transport of proteins (Fernyhough and Schmidt, 2002) and sub-optimal ion pumping (Hall et al., 1995; Huang et al., 2002; Kruglikov et al., 2004) . However, treatments with anti-oxidants such as α-lipoic acid, γ-linolenic acid and aldose reductase inhibitors have shown to prevent many indices of neuropathy in STZ-diabetic rats (Obrosova, 2002; Vincent et al., 2004; Yorek et al., 2004) .
Elevated production of reactive oxygen species (ROS) and mitochondrial hyperpolarization are exhibited by cultured endothelial cells after a short period of exposure to high [glucose] that may drive excessive electron donation to the electron transport chain in mitochondria (Nishikawa et al., 2000b) . Brownlee et al. have proposed that this mitochondrial-dependent process is a central mediator of oxidative stress in complications of diabetes (Nishikawa et al., 2000a; Nishikawa et al., 2000b) . Studies in cultured embryonic sensory neurons have shown that high [glucose] induces toxicity through an apoptotic route involving a mitochondrial-dependent pathway (Vincent et al., 2004) . But studies on adult sensory neurons from normal and STZ-diabetic rats indicate that adult neurons have different responses to high [glucose] compared with endothelial cells and embryonic neurons. Our work and studies by Wiley et al. have shown that in adult sensory neurons from STZdiabetic rats, the mitochondrial inner membrane potential is depolarized, not hyperpolarized as observed in endothelial cells exposed to high [glucose] (Huang et al., 2003; Huang et al., 2005; Srinivasan et al., 2000) . In our recent study, impaired mitochondrial respiratory chain activity was not accompanied by increased ROS production in neuronal perikarya from STZ-diabetic rats (Chowdhury et al., 2010) . However, we have recently found that ROS levels and protein adducts of 4-hydroxy-2-nonenal are elevated in the presence of high glucose concentration in axons of adult sensory neurons isolated from 3-to 5-month STZdiabetic rats, with the perikarya being unaffected (Zherebitskaya et al., 2009 ). These results suggest that mitochondrial function may differ between axons and perikarya or that oxidative stress in axons and other cells of the nerve trunk may derive from alternative sources. One of our studies also provides preliminary evidence that the sources of ROS in axons of diabetic neurons may, in part, derive from the polyol pathway. This pathway has been proposed as a source of ROS through a putative sorbitol accumulation-dependent NADPH oxidase route in previous studies (Ido et al., 2010; Oates, 2008) . In agreement with this evidence, the specific sorbitol dehydrogenase inhibitor, SDI-158, blocked high [glucose]-dependent ROS production in the axons of diabetic neurons (Akude et al., 2011) .
AMPK/SIRT/PGC-1α pathway in neurons
AMPK is a major metabolic sensor and master regulator of metabolic homeostasis (Hardie, 2007) . SIRT1 plays an important role in metabolic function and longevity in mammals. Both AMPK and SIRT1 act in concert with the master regulator of mitochondrial biogenesis, PGC-1α to regulate energy homeostasis in response to environmental and nutritional stimuli (Hardie, 2007; Reznick and Shulman, 2006) . Studies on this signaling axis in neurons remain remarkably limited. Resveratrol activates AMPK in cultured neurons (Dasgupta and Milbrandt, 2007) and in animal models of Huntington and Alzheimer's disease, PGC-1α and SIRT1 are protective (Kim et al., 2007; St-Pierre et al., 2006) . In Type 1 diabetic rats, resveratrol improved indices of neuropathy (Kumar et al., 2007; Sharma et al., 2009 ).
PGC-1α and cell metabolism
PGC-1α is a potent coactivator of a plethora of transcription factors impacting on wholebody energy expenditure, including myocyte enhancer factor-2, forkhead O-box (FOXO) transcription factors and nuclear receptors (e.g. PPARs and estrogen-related receptors) (Feige and Auwerx, 2007; Michael et al., 2001; Puigserver et al., 2003; Vega et al., 2000) . By way of these varied interactions, PGC-1α coordinately regulates gluconeogenesis, glycolysis, lipogenesis, peroxisomal and mitochondrial fatty acid oxidation, and mitochondrial respiration efficiency. PGC-1α is mainly expressed in tissues with high energy oxidative capacity such as heart, skeletal muscle, liver, brown adipose tissue and brain, and is robustly induced in conditions requiring energy, e.g. cold, fasting and exercise (Puigserver et al., 1998) . Over-expression of PGC-1α induces increased mitochondrial number and function (Lin et al., 2002) . Conversely, deletion of PGC-1α results in abnormal glucose homeostasis and decreased mitochondrial function . Decreased PGC-1α levels have been reported in skeletal muscle from insulin-resistant and Type 2 diabetic patients (Mootha et al., 2003; Patti et al., 2003; Richardson et al., 2005) . PGC-1α activity is regulated by both its expression level and by posttranslational modifications involving acetylation and phosphorylation (Rodgers et al., 2008) . Two proteins, SIRT1 and AMPK, play major roles in metabolic regulation and have recently been shown to impact on PGC-1α to transcriptionally regulate energy expenditure (Rodgers et al., 2008) .
SIRT1 and the control of PGC-1α activity
SIRT1 is a cytoplasmic enzyme (SIRT3 is the mitochondrial form) that mediates NAD + -dependent deacetylation of target substrates. SIRT1 acts as a sensor of NAD + levels that directly connects metabolic perturbations with transcriptional outputs; it was initially characterized as a histone deacetylase (Bao and Sack, 2010) . High NAD + /NADH ratios activate SIRT1, which can directly interact with and regulate the activity of transcription factors and co-regulators, including PGC-1α, PPAR-γ, p53 and the FOXO family of transcription factors (Nemoto et al., 2005; Rodgers et al., 2005) . Deacetylation of PGC-1α increases its transcriptional activity and acetyltransferase enzymes have been demonstrated to inhibit PGC-1α activity by increasing its acetylation (Canto and Auwerx, 2009 ). SIRT1-mediated regulation of PGC-1α activity may play a major role in the metabolic adaptations to energy metabolism in different tissues (Canto and Auwerx, 2010) . Recent work shows high glucose can down-regulate SIRT1 expression in endothelial cells (Balestrieri et al., 2008) and the diabetic state lowers the NAD + /NADH ratio in retina and nerve (Ido et al., 2010; Li et al., 2004; Oates, 2008; Obrosova et al., 2006) .
AMPK and linking PGC-1α activity to energy status
AMPK is a multi-component Ser/Thr kinase activated by direct binding of AMP upon a rise in the cellular AMP/ATP ratio (Hardie, 2008) . Once activated, AMPK switches on catabolic pathways to produce ATP while simultaneously shutting down energy-consuming anabolic processes. To perform these actions, AMPK quickly regulates metabolic enzymes through direct phosphorylation, but also has long-term effects at the transcriptional level to adapt gene expression to energy demands. Mice expressing a dominant-negative form of AMPK cannot increase mitochondrial biogenesis in response to energy deprivation in skeletal muscle (Zong et al., 2002) . In mice overexpressing an activated form of the AMPK-γ3 subunit, the expression of genes controlling lipid oxidation and mitochondrial activity are induced (Garcia-Roves et al., 2008) . There is a strong overlap in genes that are transcriptionally regulated by AMPK and PGC-1α, suggesting that PGC-1α may be an important mediator of AMPK-induced gene expression (Feige and Auwerx, 2007) . AMPK activation increases PGC-1α expression/phosphorylation and AMPK requires PGC-1α activity to modulate the expression of several key players in mitochondrial and glucose metabolism (Jager et al., 2007) . There is also a positive feedback loop linking AMPK with SIRT1. SIRT1 elevates AMPK activity through deacetylation of LKB1, the upstream kinase which phosphorylates and activates AMPK (Lan et al., 2008) , and AMPK enhances SIRT1 via elevation of NAD + (Bao and Sack, 2010) . Finally, high glucose concentration and/or nutrient excess leads to down-regulation of AMPK activity in several cell types (da Silva Xavier et al., 2003; .
Diabetes in mice down-regulates AMPK and PGC-1α
In DRG from STZ-diabetic Swiss Webster mice, the expression of phosphorylated (P-AMPK), and PGC-1α was decreased significantly by 8 wks (Fig. 4) . The lowered activation status of the up-stream regulators of mitochondrial biogenesis, AMPK and PGC1-α correlated with the down-regulation of an array of mitochondrial proteins confirmed by Western blotting and proteomic analysis ( (Akude et al., 2011) and Table 2 ). The most significant changes were decreased levels of mitochondrial enzyme components involved in oxidative phosphorylation (NDUFS3, COX IV), the Kreb's cycle enzyme (citrate synthase) and the oxidative stress scavenger (Mn-superoxide dismutase). In the cardiac system, diminished mitochondrial respiratory function caused by diabetes has also been identified by proteomics and gene array techniques (Bugger et al., 2008; Bugger et al., 2009 ). These broad changes in gene expression could be triggered by altered activity of key upstream regulators. In human skeletal muscle in Type 2 diabetes, the transcriptional regulator, NRF-1 and the transcriptional co-activator, PGC-1α were downregulated and corresponded with reduced expression of proteins that regulate cellular energy metabolism, including mitochondrial biogenesis and oxidative phosphorylation (Mootha et al., 2003; Patti et al., 2003) . In addition, a recent report by Iwabu et al, clarified that adiponectin (anti-diabetic adipokine) and adiponectin receptor 1 regulate PGC-1α and mitochondria through Ca 2+ and AMPK/SIRT1 (Iwabu et al., 2010) . In fact, our preliminary data identified a significant reduction in activity of SIRT3 in DRG of type 1 diabetic rodents (data not shown). Our results in STZ-diabetic mice presented in Figs. 3 and 4 along with the decreased level of SIRT3 support a causal link between AMPK/SIRT/PGC-1α pathway and mitochondrial dysfunction in sensory neuropathy developed under diabetic conditions.
Possible mechanism of induction of diabetic sensory neuropathy
Sensory neurons do not exhibit insulin-dependent glucose uptake, thus hyperglycemia leads to nutrient excess and so the AMPK/SIRT/PGC-1α pathway is deactivated. The scheme in Fig. 5 shows that this results in a general down-regulation of mitochondrial oxidative capacity and increased susceptibility to cell stress. This process is akin to the 'Crabtree effect' since ATP resources are considered by the cell body to be adequate and so oxidative phosphorylation can be deactivated and anaerobic metabolism, e.g. glycolysis, can suffice.
In highly polarized cells such as neurons this may create a unique metabolic problem in specific cellular compartments (e.g. the high energy requiring distal axon). In addition, elevated glucose flux through the polyol pathway leads to high rates of sorbitol oxidation and diminishment in the NAD + /NADH ratio (in the cytoplasm and mitochondria). This will effectively lower NAD + levels and so reduce SIRT1/3 activity. In addition, the raised NADH levels will enhance oxidative stress, in part, through elevated NADPH oxidase as proposed by Williamson et al (Ido et al., 2010) . Our recent paper provides pharmacological evidence that sorbitol oxidation contributes to oxidative stress in axons of diabetic neurons (see Figure 5 in (Akude et al., 2011) ).
Another aspect of mitochondrial biology that may be relevant to diabetic neuropathy is the possible involvement of autophagosomes. The presence of increased levels of autophagosomes in DRG neurons of STZ-induced diabetic rats with the co-localization of mitochondria in neuronal soma described by Towns et al. suggests that autophagy may be indicative of, or may contribute to, the mitochondrial dysfunction in diabetic neuropathy (Towns et al., 2008; Towns et al., 2005) . Our hypothesis detailing a diabetes-dependent shift towards an anaerobic source of ATP would support the need to remove unnecessary or dysfunctional mitochondria -and this would be reflected by elevated autophagy of this organelle. However, while the work from the Wiley group is interesting further confirmation is needed and in particular ultrastructural identification of autophagosomes is required over a time course of development of diabetic neuropathy. At this juncture numerous electron microscope-based ultrastructural studies of DRG neuronal perikarya from human, STZinduced and BB diabetic rats have been performed over the years but have failed to identify the classic double membrane structure of this organelle (Kamiya et al., 2006; Schmidt et al., 1997b ).
In conclusion, we hypothesize that high glucose-induced AMPK/SIRT/PGC-1α downregulation in neurons is a maladaptive process that explains the length dependent loss of distal nerve endings. The constantly plastic axonal endings of fibers in the skin require enormous amounts of ATP to be maintained and to permit collateral sprouting (Bernstein and Bamburg, 2003) . This in turn demands a sufficient supply of actively respiring mitochondria. Hyperglycemia-induced loss of the AMPK/SIRT/PGC-1α pathway in diabetic neurons may lead to a dearth of fully functioning mitochondria that ultimately triggers distal axonal death, a hallmark of severe diabetic peripheral neuropathy.
Summary
Mitochondrial dysfunction occurs in a range of diabetic complications and given its central role in controlling the bioenergetic status of the cell must be considered a prime trigger of degeneration. It remains unclear how such impaired mitochondrial function triggers cell damage. Enhanced ROS production remains an unproven possibility. Failure to synthesize adequate ATP for high energy requiring axonal functions such as excitation, axonal transport and growth cone motility would seem more attractive options, particularly in neurons. In diabetic neuropathy, studies have begun to outline the array of impairments in mitochondrial physiology, although studies still lag behind those in nephropathy and cardiomyopathy. Diabetes-induced changes in mitochondrial phenotype would seem key factors leading to altered activity of the respiratory chain and Krebs cycle components. Aberrant growth factor-dependent signaling, especially through the insulin pathway could be involved (Ishii, 1995; Zochodne, 2008) , however, hyperglycemia and associated raising of intracellular glucose concentration maybe a central trigger of altered mitochondrial proteome expression. In many cell types, high intracellular glucose causes inhibition of oxidative phosphorylation and enhances anaerobic glucose metabolism through glycolysis, known as the Crabtree effect (Ibsen, 1961) . The glucose-dependent signal transduction pathway that is proposed to become active in the diabetic state and that initiates altered cell bioenergetics in neurons needs to be dissected and manipulated in vitro and in vivo. There is a plausible role for the polyol pathway in such a paradigm, however, it must be remembered that neurons do not express aldose reductase and so the activity of such a pathway in neurons in diabetes remains unclear (Jiang et al., 2006) .
The involvement of deacytylases, such as the sirtuins, along with AMPK and PGC-1α in the mitochondrial dysfunction seen in sensory neuropathy could explain the broad array of phenotypic changes that underlie the altered mitochondrial physiology observed. There is a strong level of inter-dependence between the AMPK, SIRT and PGC1α components in diabetic neuropathy. Therefore, a focus on the AMPK/SIRT/PGC-1α pathway in sensory neurons will provide a novel approach to explaining its role on the pathogenesis of the distal axonopathy seen in diabetes and its potential for pharmacologic targeting to help reverse features of the sensory neuropathy. However, given the central nature of this pathway to energy homeostasis in numerous tissues, a major challenge will likely be avoiding untoward side effects that impair their function in non-target tissues. Nutrient excess or hyperglycemia combines to alter mitochondrial function. High intracellular [glucose] in neurons may cause a general downregulation of mitochondrial oxidative capacity, possibly through the involvement of AMPK/PGC-1α pathway. Under nutrient depletion (starvation, exercise) or the influence of resveratrol or AICAR, the pathway is activated. In addition, elevated glucose flux through the polyol pathway leads to high rates of sorbitol oxidation and a decrease in the cytoplasmic and mitochondrial NAD + / NADH ratio. This will effectively lower NAD + levels and reduce SIRT1/3 activity. There is also a positive feedback loop linking AMPK with SIRT1 wherein SIRT1 elevates AMPK activity through deacetylation of LKB1 and AMPK enhances SIRT1 through elevation of NAD + . Table 2 represents a summary of our own mass spectrometry data of protein expression related to mitochondria and affected by diabetes and its correction by insulin therapy. Changes in percent represent the effect of insulin treatment on the protein expression ratio measured from diabetic rats. Copyright 2011 American Diabetes Association. From Diabetes, vol. 60, 2011; 291. Reprinted with permission from the American Diabetes Association.
